Abiopharma

🔍 Xu Cong Claire (Executive)

Company: NovaBridge Biosciences (NBP)

Report Date: 2026-08-30

Detailed Transactions and Holdings:

• Acquired 9,382 shares of Ordinary Shares (Direct)
  Date: 2026-08-30 | Code: M | equity_swap_involved: 0 | shares_owned_after: 307,483.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F4
• Sold 3,282 shares of Ordinary Shares at $0.79 per share (Direct)
  Date: 2026-08-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 304,201.00 | transaction_form_type: 4 | Footnotes: F1, F5, F6, F7
• Sold 4,079 shares of Restricted Share Units (Derivative)
  Date: 2026-08-30 | Code: M | equity_swap_involved: 0 | shares_owned_after: 28,558.00 | transaction_form_type: 4 | Footnotes: F3, F8, F9, F9, F1, F8

Footnotes:

• F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
• F2: Reported securities are represented by 4,079 ADSs.
• F3: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
• F4: Reported securities are represented by 133,688 ADSs.
• F5: Reported securities are represented by 1,427 ADSs.
• F6: Reported sales price represents the converted sales price of the ADSs of $1.8186.
• F7: Reported securities are represented by 132,261 ADSs.
• F8: Reported securities represent ADSs.
• F9: On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.